netFormulary Portsmouth and South East Hampshire NHS
Prescribing Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Chapter Links...
 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Abemaciclib (Verzenios®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England
 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Abemaciclib (Verzenios®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

 
   
Alectinib (Alecensa®)
(Capsule)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

 
   
Atezolizumab  (Tecentriq® )
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Link  NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Link  NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
   
Avelumab (Bavencio®)
(Concentrate solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 517 Avelumab for treating metastatic Merkel cell carcinoma
   
Axicabtagene ciloleucel (YESCARTA®)
(Cell dispersion for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 559 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
   
Axitinib (Inlyta®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA333: Axitinib for advanced renal cell carcinoma
   
Binimetinib (Mektovi ®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Bosutinib (Bosulif®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
   
Brigatinib (Alunbrig®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Carfilzomib (Kyprolis®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 457 Carfilzomib for previously treated multiple myeloma
   
Cytotoxic Drug Cemiplimab (Libtayo®)
(Concentrate for solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
   
Ceritinib (Zykadia)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
   
Dabrafenib (Tafinlar®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Link  NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
Dacomitinib monohydrate (Vizimpro®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Daratumumab (Darzalex®)
(Concentrate solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
Dinutuximab beta (Qarziba®)
(Infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

NICE TA 538: Dinutuximab beta for treating neuroblastoma

 
   
Durvalumab (Imfinzi®)
(solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
   
Encorafenib (Braftovi®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Cytotoxic Drug Eribulin (Halaven®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
   
Gemtuzumab ozogamicin (Mylotarg®)
(powder concentrate for solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
 
Link  NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
   
Ibrutinib (Imbruvica®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia
Link  NICE TA 491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Link  NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
   
Idelalisib (Zydelig®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
   
Inotuzumab ozogamicin (Besponsa®)
(Concentrate for solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

NICE TA541 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

 
   
Lenvatinib (Lenvima®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Cancer Drugs Fund
 
Link  NICE TA 535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Link  NICE TA 551 Lenvatinib for untreated advanced hepatocellular carcinoma
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Liposomal cytarabine-daunorubicin (Vyxeos®)
(powder for concentrate for solution for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
   
Lutetium (177Lu) oxodotretide (Lutathera®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

NICE TA539 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours

 
   
Midostaurin (Rydapt®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
 
Link  Midostaurin for untreated acute myeloid leukaemia
   
Neratinib  (Nerlynx ®)
(film coated tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England
 
Link  NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
   
Niraparib  (Zejula®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
   
Cytotoxic Drug Panitumumab (Vectibix®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
Cytotoxic Drug Panobinostat (Farydak®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
   
Pembrolizumab (Keytruda®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Link  NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Link  NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Link  NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Link  NICE TA522Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Link  NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Link  NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Link  NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Link  NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
   
Ponatinib (Iclusig®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 451 Ponatinib for treating CML and ALL
   
Rucaparib (Rubraca®)
(film coated tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
 
Link  NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
   
Ruxolitinib (Jakavi®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
   
Cytotoxic Drug Talimogene laherparepvec (Imlygic®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
   
Tisagenlecleucel (Kymriah®)
(Cell dispersion for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
 
Link  NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Link  NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
   
Tivozanib (Fotivda®)
(890microgram and 1340microgram hard capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 512 Tivozanib for treating advanced renal cell carcinoma
   
Trametinib (Mekinist®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
   
Venetoclax
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund

In line with NICE TA487  

 
Link  NICE TA 487 Venetoclax for treating chronic lymphocytic leukaemia
Link  NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
   
08.01.05  Expand sub section  Arsenic trioxide
Cytotoxic Drug Arsenic Trioxide (Trisenox®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia
   
08.01.05  Expand sub section  Bevacizumab
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
Cytotoxic Drug Bortezomib (Velcade®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA129: Multiple myeloma - bortezomib
Link  NICE TA228: 1st line treatment of multiple myeloma
Link  NICE TA311: Bortezomib for induction therapy in multiple myeloma
Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Link  NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
   
08.01.05  Expand sub section  Brentuximab vedotin
Brentuximab vedotin (Adcetris®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Link  NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
   
08.01.05  Expand sub section  Cetuximab
Cetuximab (Erbitux®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Link  NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
   
08.01.05  Expand sub section  Crisantaspase
Crisantaspase (Erwinase®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Dacarbazine and Temozolomide
Cytotoxic Drug Dacarbazine
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Temozolomide
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA121: Glioma (newly diagnosed and high grade)
Link  NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
   
08.01.05  Expand sub section  Erlotinib to top
Erlotinib (Tarceva® )
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Link  NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
08.01.05  Expand sub section  Hydroxycarbamide
Cytotoxic Drug Hydroxycarbamide
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber with Shared Care
 
Link  Hydroxycarbamide Shared Care Guideline August 2019
   
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
Ipilimumab (Yervoy®)
(Injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
   
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab to top
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
Cytotoxic Drug Carboplatin
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Cisplatin
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
Cytotoxic Drug Oxaliplatin
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
   
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
Cytotoxic Drug Procarbazine
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Protein kinase inhibitors to top
Afatinib (Giotrif®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
   
Cabozantinib (Cabometyx®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA 463 Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

For treating medullary thyroid cancer

 
Link  NICE TA 516 Cabozantinib for treating medullary thyroid cancer
   
Crizotinib (Xalkori®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 422 Crizotinib for previously treated ALK-positive advanced non-small-cell lung cancer
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
   
Dasatinib (Sprycel®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Erlotinib (Tarceva®)
(tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA 258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Link  NICE TA 374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Everolimus (Afinitor®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA 432 Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours
   
Gefitinib (Iressa®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Cytotoxic Drug Imatinib
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Link  NICE TA 326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Link  NICE TA 70 Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA 86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
   
Lapatinib (Tyverb®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
   
Nilotinib (Tasigna®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Link  NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Nintedanib  (Vargatef®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA 347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
   
Pazopanib (Votrient®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA 555 Regorafenib for previously treated advanced hepatocellular carcinoma
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 474 Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib (Sutent®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
   
Vemurafenib (Zelboraf®)
(Tablets)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
   
08.01.05  Expand sub section  Taxanes
Cytotoxic Drug Cabazitaxel (Jevtana®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
   
Cytotoxic Drug Docetaxel
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Link  NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
   
Cytotoxic Drug Paclitaxel
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
 
Link  NICE TA 476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
   
08.01.05  Expand sub section  Topoisomerase I inhibitors
Cytotoxic Drug Irinotecan Hydrochloride
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE CG 131 Colorectal cancer: diagnosis and management
   
Cytotoxic Drug Topotecan
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA 389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Link  TA 183 Topotecan for the treatment of recurrent and stage IVB cervical cancer
   
Cytotoxic Drug Topotecan (Hycamtin®)
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA184: Lung cancer (small-cell) - topotecan
   
08.01.05  Expand sub section  Trabectedin
Cytotoxic Drug Trabectedin (Yondelis®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
Link  NICE TA185: Soft tissue sarcoma - trabectedin
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
   
08.01.05  Expand sub section  Trastuzumab
Cytotoxic Drug Pertuzumab (Perjeta®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA 424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Link  NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
   
Cytotoxic Drug Trastuzumab (Herceptin®)
(Infusion, subcutaneous injection)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Subcutaneous injection licensed for breast cancer only.

 
Link  NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Link  NICE TA34: Breast cancer - trastuzumab
   
Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
(for infusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Cancer Drugs Fund
 
Link  NICE TA 458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer
   
08.01.05  Expand sub section  Tretinoin to top
Tretinoin
(Capsules)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
 
   
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Cytotoxic Drug  Aflibercept  (Zaltrap®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
 
Bevacizumab  (Avastin®)
(Oncology)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
Link  NICE TA214: Breast Cancer with taxane
Link  NICE TA263: Breast cancer with capecitabine
Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
 
Bexarotene  (Targretin®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cabozantinib  (Cometriq®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Cancer Drugs Fund
 
Cytotoxic Drug  Eribulin  (Halaven®)
(Injection)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary Non-formulary for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Link  NICE TA 515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
 
Everolimus  (Votubia®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
 
Mitotane  (Lysodren®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Necitumumab  (Portrazza®)
(for infusion)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
High Cost Medicine

NOT recommended in TA 411 - not cost-effective

Link  NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
 
Olaratumab  (Lartruvo® )
(for infusion)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary

LILLY STATEMENT January 2019

No new patients should be prescribed olaratumab

Physicians may consider continuing treatment in patients who experience clinical benefit.

MHRA June 2019 statement:

The ANNOUNCE 3 study failed to show a clinical benefit.

For patients currently on therapy, consider alternative treatment options since available stock will expire by April 2020.

Link  NICE TA 465 Olaratumab with doxorubicin for treating advanced soft tissue sarcoma
 
Pablociclib  (Ibrance®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Cytotoxic Drug  Pentostatin  (Nipent®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Ramucirumab  (Cyramza®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Link  NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
Cytotoxic Drug  Vismodegib  (Erivedge®)

View adult BNF View SPC online View childrens BNF
Non Formulary
High Cost Medicine
Cancer Drugs Fund
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Primary and Secondary Care (unrestricted) – may be prescribed by GPs, hospital doctors or other qualified prescribers in primary and secondary care  

Amber Initiation

Amber Initiated: first prescription from specialist, on going supplies from primary care (or when stabilised on therapy).  

Amber Recommended

Amber recommended: first prescription may be supplied by primary care under the advice of a specialist.  

Amber with Shared Care

For initiation within a specialist service followed by ongoing prescribing in primary care according to published shared care guidance  

Red

For initiation and ongoing prescribing in secondary care only. Medicines in this category may be further restricted to use by specific hospital departments only.  

Blue

For prescribing in primary care only  

netFormulary